
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is seeing a decline in Baqsimi sales due to lower selling prices and changes in the channel mix, which has resulted in an overall decrease in revenue for the company. However, the company's launch of ipratropium bromide HFA in 2Q26 and continued growth in prescriptions for Baqsimi show potential for future revenue growth. Despite current challenges, Amphastar's diverse product portfolio, strong presence in major markets like the U.S., China, and France, and its focus on developing challenging generic and proprietary products make it a promising stock option.
Bears say
Amphastar Pharma is facing multiple issues both with current product declines and potential product launches. With recent pricing headwinds impacting Baqsimi's sales growth expectation, it remains unclear when the company's pipeline opportunities will translate into actual revenue growth, making it difficult to project top-line and EBITDA growth. Additionally, the significant stock ownership of company directors and executive officers may lead to potential conflicts of interest and influence over important corporate decisions. Overall, these factors contribute to a negative outlook on Amphastar Pharma's stock.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares